First disclosure of our CCR8 antagonist IPG7236 and its optimization story in Journal of Medicinal Chemistry. The compound exhibited excellent PK profile in human as well as promising anti-tumor activity in Phase I and will be advanced into Phase II stage soon.
Click here to learn more
